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Choices in health care spending
To the Editor. It is encouraging that the US Medical Director of
a major drug company endorses the concept of 'accountability
for reasonableness' .' However, the company's position cannot
be accepted uncritically. Drug companies often emphasise cost-
effectiveness analyses as the primary factor in deciding
whether or not a new drug is 'affordable' . Thus the drug
company promoting an expensive new product asserts, as in
the case of Xigris, that the cost of just under US$50 000 per
quality-adjusted life-year saved compares favourably with
other procedures (e .g . kidney transplantation) .
In our editorial' we rejected a narrow, technically orientated
approach . We argued that although highly technical procedures
such as calculations of cost-effectiveness and estimates of life-
years saved are necessary, this must not be the only factor
considered in making allocation choices. A decision about how
to spend society's limited medical resources is a value
judgement that specifies and balances all morally relevant
factors - including distributive justice, social utility and
economic efficiency - without giving any single one an a priori
advantage.' In the case of an expensive new drug such as
Xigris society may, when forced to make a tough choice,
reasonably decide that its moral values compel saving or
extending the lives of identifiable patients - say those afflicted
with HIV/AIDS or patients who may be cured with a kidney
transplant - rather than the few who could be saved by
paying an equivalent amount to treat 16 patients in order to
save one unidentifiable life .
Cost-effectiveness analyses based on US dollars are largely
irrelevant to South Africa and other developing countries . The
US alone spends more than 50% (US$1.2 trillion - 14% GDP,
with per capita expenditure of almost $5 000) of the total health
care expenditure in the world on 5% of the world's population .
In contrast, South Africa spends about 8.1 % of GDP on health
care, with a public sector health services budget of US$3.4
billion in 2000/01 - about 4% of GDP, amounting to R779 per
person (approximately $100 per capita) . South Africa ranks 94
on the Human Development Index, not far above Zimbabwe at
117 . South Africa's health administrators must be very selective
about what they learn positively from recommendations from
the US, and there is much negative that we can learn from
them . Drugs that are affordable as a matter of course in the US
and other rich nations may not be relevant or affordable in our
context.
Debate such as has occurred in this and the previous issue of
SAMJ should be encouraged . However, the discussion must be
carried forward in full recognition by all stakeholders of the
stark realities that face health administrators in South Africa .
Demands for health services have increased exponentially, and
the capacity of the public sector to proved decent quality
services to all citizens has shrunk. The AIDS pandemic will
July 2003, Vol . 93, No . 7 SAMJ
exacerbate an already critical situation . It is in this context that
our health administrators must assess the claims of drug
companies and manufacturers, often based on data and cost-
effectiveness analyses more relevant and useful in the rich
countries of the developed world than in developing countries
like South Africa .
S R Benatar
T E Fleischer
Bioethics Centre
University of Cape Town
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Drotrecogin alfa (activated) in
South African private hospital
ICUs
To the Editor: We wish to comment on the article by Taylor
and Burns .' They advance several concerns with the PROWESS
trial of drotrecogin alfa (activated protein C) (DroAA) in severe
sepsis' as reasons for withholding this agent from patients
covered by their medical scheme in South Africa . These
concerns may be valid and have been extensively debated at
both local and international congresses . However, the fact is
that DroAA is accepted by the FDA in the USA and regulatory
authorities in Europe as an effective treatment of severe sepsis.
Bleeding complications are an inherent risk of all drugs with
anticoagulant activity, including heparins, warfarin and
antiplatelet agents . Excess bleeding in trial patients has not
prevented various anticoagulants from being used in the
treatment of thrombotic disorders such as acute myocardial
infarction and deep-vein thrombosis, especially with
pulmonary embolisation. Healthy debate follows the
introduction of any new intervention in medical practice but
cannot be cited by funders, whose primary concern is financial
rather than clinical, as an excuse to withhold even expensive
treatment from deserving patients . By the current standards of
evidence-based medicine, DroAA is an acceptable agent for
treatment of severe sepsis .
DroAA is particularly important in the treatment of patients
with meningococcal septicaemia,' in which situation it was
available on compassionate grounds throughout the world
before release . Should the agent be withheld from patients with
meningococcal septicaemia, the risk of complications is
dramatically increased and mortality and length of stay in the
ICU and in hospital are increased . The cost of the agent in this
setting will be more than offset by the reduced need for ICU
and hospital care, as demonstrated by a recent case in
